Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Psoriatic Arthritis | Unmet Need | US/EU | 2024

Login to access report north_east
Contact sales account_box

TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, howeverbut competing biologics such as IL-17 inhibitors (Cosentyx, Taltz, Bimzelx), IL-12/23 inhibitors (Stelara), IL-23 inhibitors (Tremfya, Skyrizi), and targeted oral therapies such as PDE4 inhibitors and selective JAK inhibitors (Otezla, Xeljanz, Rinvoq) are increasingly challenging the dominance of TNF-alpha inhibitors in treating PsA. Moreover, many patients do not respond adequately to these agents, necessitating alternative treatment strategies. Thus, rRecognizing gaps in PsA treatment and focusing on product differentiation may play a crucial role in an agent’s success in this competitive PsA space. This report outlines key unmet needs and offers tools for strategic decision-making in the PsA therapy market.

QUESTIONS ANSWERED

  • How do current therapies perform on key treatment drivers and goals for PsA?
  • When considering Humira, Cosentyx, Taltz, Otezla, Rinvoq, Bimzelx, Skyrizi, and others wWhich drug attributes are key influencers, which have limited impact, and which are hidden opportunities in PsA?
  • What are the prevailing areas of unmet need and opportunity in the PsA market?
  • What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new PsA drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European rheumatologists and dermatologists fielded in DecemberFebruary 2024

Key companies: AbbVie, Amgen, UCB, Pfizer, Johnson & Johnson Innovative Medicine, Novartis, Eli Lilly

Key drugs: Humira, Cosentyx, Taltz, SkyriziStelara, BimzelxTremfya, Otezla, Rinvoq

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
north_east
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
north_east
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
north_east
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east